Abstract
Changes in rRNA and rDNA expression have been associated with cellular and organism aging and have been linked to Alzheimer’s disease (AD) pathogenesis. In this study, we investigated the mRNA expression of ribosomal genes (28S/18S) and β-amyloid precursor protein (APP) in different post mortem brain tissue regions (the entorhinal and auditory cortices and the hippocampus) of AD patients and elderly control subjects and also evaluated the extent of expression in peripheral blood from young, healthy, elderly, and Alzheimer’s disease patients in order to investigate whether these individuals experienced the effects of aging. The comparative threshold cycle (CT) method via Real Time Polymerase Chain Reaction and the Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP) were used to analyze gene expression and the Apolipoprotein E (APOE) genotype, respectively. When the brain areas were analyzed collectively, we observed a significant decrease in APP expression and a significant increase in levels of mRNA of 18S and 28S in Alzheimer’s disease patients compared to healthy elderly individuals. Furthermore, there was a significant upregulation of 28SrRNA in the entorhinal cortex and hippocampus, but not in the auditory cortex of patients with AD. On the other hand, tests of blood samples verified a decreased expression of 28S rRNA in patients with AD. These results support the hypothesis that changes in rRNA are present in AD patients, are tissue-specific, and seem to occur independently and differently in each tissue. However, the next challenge is to discover the mechanisms responsible for the differences in expression observed in the blood and the brain in both healthy elderly individuals and Alzheimer’s disease patients, as well as the impact of these genes on AD pathogenesis.
Keywords: Alzheimer’s disease, brain, blood, ribosomal genes, 18S, 28S.
Current Alzheimer Research
Title:Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Volume: 12 Issue: 10
Author(s): Lucas Rasmussen, Roger W. de Labio, Gustavo A. Viani, Elizabeth Chen, Joao Villares, Paulo-Henrique Bertolucci, Thais S. Minett, Gustavo Turecki, Danielle Cecyre, Sandra A. Drigo, Marilia C. Smith and Spencer L.M. Payao
Affiliation:
Keywords: Alzheimer’s disease, brain, blood, ribosomal genes, 18S, 28S.
Abstract: Changes in rRNA and rDNA expression have been associated with cellular and organism aging and have been linked to Alzheimer’s disease (AD) pathogenesis. In this study, we investigated the mRNA expression of ribosomal genes (28S/18S) and β-amyloid precursor protein (APP) in different post mortem brain tissue regions (the entorhinal and auditory cortices and the hippocampus) of AD patients and elderly control subjects and also evaluated the extent of expression in peripheral blood from young, healthy, elderly, and Alzheimer’s disease patients in order to investigate whether these individuals experienced the effects of aging. The comparative threshold cycle (CT) method via Real Time Polymerase Chain Reaction and the Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP) were used to analyze gene expression and the Apolipoprotein E (APOE) genotype, respectively. When the brain areas were analyzed collectively, we observed a significant decrease in APP expression and a significant increase in levels of mRNA of 18S and 28S in Alzheimer’s disease patients compared to healthy elderly individuals. Furthermore, there was a significant upregulation of 28SrRNA in the entorhinal cortex and hippocampus, but not in the auditory cortex of patients with AD. On the other hand, tests of blood samples verified a decreased expression of 28S rRNA in patients with AD. These results support the hypothesis that changes in rRNA are present in AD patients, are tissue-specific, and seem to occur independently and differently in each tissue. However, the next challenge is to discover the mechanisms responsible for the differences in expression observed in the blood and the brain in both healthy elderly individuals and Alzheimer’s disease patients, as well as the impact of these genes on AD pathogenesis.
Export Options
About this article
Cite this article as:
Rasmussen Lucas, de Labio W. Roger, Viani A. Gustavo, Chen Elizabeth, Villares Joao, Bertolucci Paulo-Henrique, Minett S. Thais, Turecki Gustavo, Cecyre Danielle, Drigo A. Sandra, Smith C. Marilia and Payao L.M. Spencer, Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients, Current Alzheimer Research 2015; 12 (10) . https://dx.doi.org/10.2174/1567205012666151027124017
DOI https://dx.doi.org/10.2174/1567205012666151027124017 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Elimination of the Causes of Poor Sleep Underlying Delirium is a Basic Strategy to Prevent Delirium
Current Molecular Pharmacology NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy
Current Pharmaceutical Design Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry Aβ Monomers, Oligomers and Fibrils: Structural Features
Current Bioactive Compounds Sleep-Related Disorders, Diabetes and Obesity: Understanding the Facts
Current Respiratory Medicine Reviews Blast from the Past: The Aluminums Ghost on the Lanthanum Salts
Current Medicinal Chemistry Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Nanoparticlized System: Promising Approach for the Management of Alzheimer’s Disease through Intranasal Delivery
Current Pharmaceutical Design MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research <i>Nigella sativa</i> L., Supplementary Plant with Anticholinesterase Effect for Cognition Problems: A Kinetic Study
Current Aging Science A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Microglial Proteases: Strategic Targets for Neuroprotective Agents
Current Neuropharmacology Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Zolpidem Therapy for Movement Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry